Evidence map›Paper›PMID 41062692›Full record

ArticleNature2025

KCTD10 is a sensor for co-directional transcription-replication conflicts.

Jake A Kloeber, Bin Chen, Guangchao Sun, Charles S King, Zhiquan Wang, Li Wang, Zheming Wu, Shouhai Zhu, Fei Zhao, Hongran Qin and 11 more

Abstract read
In one paragraph

Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. A gut instinct for microbial patterns.Nature reviews. Neuroscience · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jake A Kloeber *Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-6646-564X
Bin Chen *Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Guangchao SunAdvanced Diagnostic Laboratory, Quantitative Health Sciences Department, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-3942-6175
Charles S KingDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.ORCID 0009-0006-6905-6792
Zhiquan WangDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-8243-7251
Li WangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Zheming WuDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.ORCID 0009-0008-2248-0654
Shouhai ZhuDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Fei ZhaoDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Hongran QinDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Yaobin OuyangDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Huaping XiaoDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Xinyi TuDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Jing LuDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Yanxia JiangDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Kuntian LuoDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Ping YinDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Xinyan WuDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Robert W MutterDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Jinzhou HuangDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA. huang.jinzhou@mayo.edu.ORCID 0000-0002-5956-0905
Zhenkun LouDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA. lou.zhenkun@mayo.edu.ORCID 0000-0003-1938-3091

Funding

ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
MSTP at Mayo Clinic RochesterT32GM145408 · NIGMS · MAYO CLINIC ROCHESTER · PI SCOTT H KAUFMANN, LISA A SCHIMMENTI · 2023 to 2026
$4.7M
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatmentR01CA264600 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2021 to 2025
$1.8M
Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancerR01CA285345 · NCI · MAYO CLINIC ROCHESTER · PI Josep Maria Domingo-Domenech, Zhenkun Lou · 2024 to 2026
$1.5M
NCI NIH HHS R01 CA264600NCI NIH HHS R01 CA285345NIGMS NIH HHS R01 GM129325NIGMS NIH HHS T32 GM145408
6 · The paper itself

Abstract

During DNA replication, the replisome must remove barriers and roadblocks including the transcription machinery

Indexed as

Cullin ProteinsDNA ReplicationPotassium Channels, Voltage-GatedTranscription, GeneticDNA DamageDNA-Directed RNA PolymerasesHumansMultienzyme ComplexesMultiprotein ComplexesUbiquitinationUbiquitin-Protein LigasesCUL3 protein, humanCullin ProteinsDNA-Directed RNA PolymerasesKCTD10 protein, humanMultienzyme ComplexesMultiprotein ComplexesPotassium Channels, Voltage-GatedUbiquitin-Protein Ligases

Identifiers

PMID41062692
PMCPMC12675284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.